Search research articles
Contact Us
Filters
Showing results (501-510 of 573) with videos related to
Page
of 58
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2010
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial
Rachel S Midgley, Christopher C McConkey, Elaine C Johnstone, et al.
Antiviral Therapy
|
October 14, 2015
Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS)
Lisa Hamzah, Juan M Tiraboschi, Helen Iveson, et al.
Molecules (Basel, Switzerland)
|
March 22, 2019
Amyloid-Targeting PET Tracer [<sup>18</sup>F]Flutemetamol Accumulates in Atherosclerotic Plaques
Sanna Hellberg, Johanna M U Silvola, Heidi Liljenbäck, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 16, 2006
Initial results of screening of nondiabetic organ donors for expression of islet autoantibodies
R Gianani, A Putnam, T Still, et al.
Disasters
|
March 12, 2026
Enablers of community-led action in Australian climate disasters: recognising the role of pre-existing social foundations and local knowledges
Scott Webster, David Schlosberg, Jo Longman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2001
Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer
D L Clarke-Pearson, L Van Le, T Iveson, et al.
The Lancet. Oncology
|
June 27, 2014
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
Timothy Iveson, Ross C Donehower, Irina Davidenko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2004
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer
S Rao, D Cunningham, A de Gramont, et al.
Frontiers in Immunology
|
July 6, 2018
Activation of the Immune-Metabolic Receptor GPR84 Enhances Inflammation and Phagocytosis in Macrophages
Carlota Recio, Daniel Lucy, Gareth S D Purvis, et al.
Clinical Colorectal Cancer
|
May 16, 2021
Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis
Catherine R Hanna, Jose A Robles-Zurita, Andrew Briggs, et al.
Page
of 58
Search research articles
Search
Showing results (501-510 of 573) with videos related to
Sort By:
Page
of 58
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2010
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial
Rachel S Midgley, Christopher C McConkey, Elaine C Johnstone, et al.
Antiviral Therapy
|
October 14, 2015
Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS)
Lisa Hamzah, Juan M Tiraboschi, Helen Iveson, et al.
Molecules (Basel, Switzerland)
|
March 22, 2019
Amyloid-Targeting PET Tracer [<sup>18</sup>F]Flutemetamol Accumulates in Atherosclerotic Plaques
Sanna Hellberg, Johanna M U Silvola, Heidi Liljenbäck, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 16, 2006
Initial results of screening of nondiabetic organ donors for expression of islet autoantibodies
R Gianani, A Putnam, T Still, et al.
Disasters
|
March 12, 2026
Enablers of community-led action in Australian climate disasters: recognising the role of pre-existing social foundations and local knowledges
Scott Webster, David Schlosberg, Jo Longman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2001
Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer
D L Clarke-Pearson, L Van Le, T Iveson, et al.
The Lancet. Oncology
|
June 27, 2014
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
Timothy Iveson, Ross C Donehower, Irina Davidenko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2004
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer
S Rao, D Cunningham, A de Gramont, et al.
Frontiers in Immunology
|
July 6, 2018
Activation of the Immune-Metabolic Receptor GPR84 Enhances Inflammation and Phagocytosis in Macrophages
Carlota Recio, Daniel Lucy, Gareth S D Purvis, et al.
Clinical Colorectal Cancer
|
May 16, 2021
Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis
Catherine R Hanna, Jose A Robles-Zurita, Andrew Briggs, et al.
Page
of 58